HexaBody-DR5/DR5

HexaBody®-DR5/DR5 is a mixture of two non-competing HexaBody molecules that target two distinct epitopes on death receptor 5 (DR5), a cell surface receptor that mediates a process called programmed cell death, which is very important for the natural elimination of cells. HexaBody-DR5/DR5 is the first HexaBody molecule to enter the clinic and it has potential in a variety of solid tumors including colorectal cancer, non-small cell lung cancer, triple negative breast cancer, renal cell cancer & urothelial cancer. During the fourth quarter of 2017 both an IND and a CTA were filed for HexaBody-DR5/DR5 with a Phase I/II study planned to start in 2018.

Back to top

HexaBody-DR5/DR5 has potential in a variety of solid tumors including colorectal cancer, non-small cell lung cancer, triple negative breast cancer, renal cell cancer & urothelial cancer. A Phase I/II study planned to start in 2018.

Back to top